Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How to determine the mechanism of action of CFTR modulator compounds: A gateway to theranostics
Margarida D. Amaral
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112989-112989
Closed Access | Times Cited: 12

Showing 12 citing articles:

Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis
Luca Cavinato, Francesco R. Luly, Valentina Pastore, et al.
European Respiratory Journal (2022) Vol. 61, Iss. 4, pp. 2200725-2200725
Open Access | Times Cited: 24
Global Functional Genomics Reveals GRK5 as a Cystic Fibrosis Therapeutic Target Synergistic with Current Modulators
Hugo M. Botelho, Miquéias Lopes‐Pacheco, Madalena C. Pinto, et al.
iScience (2025) Vol. 28, Iss. 3, pp. 111942-111942
Open Access
Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis
Madalena C. Pinto, Iris A. L. Silva, Miriam Frankenthal Figueira, et al.
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 693-723
Open Access | Times Cited: 32
Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids
Iris A. L. Silva, Violeta Railean, Aires Duarte, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 5, pp. 421-421
Open Access | Times Cited: 23
Synthesis and Biological Evaluation of Pyrazole–Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
Christian Vaccarin, Guido Veit, Tamás Hegedűs, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13891-13908
Closed Access | Times Cited: 2
Precision medicine for rare diseases: The times they are A-Changin'
Margarida D. Amaral
Current Opinion in Pharmacology (2022) Vol. 63, pp. 102201-102201
Closed Access | Times Cited: 11
Mislocalization of CFTR expression in acute pancreatitis and the beneficial effect of VX‐661 + VX‐770 treatment on disease severity
Gabriella Fűr, Emese Réka Bálint, Erik Márk Orján, et al.
The Journal of Physiology (2021) Vol. 599, Iss. 22, pp. 4955-4971
Open Access | Times Cited: 10
To explore the pharmacological mechanism of action using digital twin
Hidayat Ur Rahman
International Journal of ADVANCED AND APPLIED SCIENCES (2022) Vol. 9, Iss. 2, pp. 55-62
Open Access | Times Cited: 6
Clinical and Genetic Characterisation of Cystic Fibrosis Patients in Latvia: A Twenty-Five-Year Experience
Madara Auzenbaha, Elina Aleksejeva, Gita Tauriņa, et al.
Diagnostics (2022) Vol. 12, Iss. 11, pp. 2893-2893
Open Access | Times Cited: 3
Using the genome to correct the ion transport defect in cystic fibrosis
Margarida D. Amaral
The Journal of Physiology (2022) Vol. 601, Iss. 9, pp. 1573-1582
Closed Access | Times Cited: 1
Pharmacological approaches to cystic fibrosis
Tiziano Bandiera, Luis J. V. Galietta
European Journal of Medicinal Chemistry (2021) Vol. 216, pp. 113240-113240
Closed Access
Novel CFTR Modulators for Treating Cystic Fibrosis
R. W. Sabnis
ACS Medicinal Chemistry Letters (2021) Vol. 12, Iss. 6, pp. 949-950
Open Access
Page 1

Scroll to top